- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00428662
Evaluation of a New Nanotechnology Based Drug-Eluting Stent for Opening of Narrowed Arteries of the Heart
January 29, 2007 updated by: All India Institute of Medical Sciences, New Delhi
Clinical and Angiographic Evaluation of Paclitaxel Eluting, Non-Polymeric, Nanoporous Carbon-Carbon Coated, Cobalt-Chromium Stent
Coronary artery disease (CAD) is the largest cause of death and disability in the world.
Besides medicines, the principle treatment of this condition requires opening of the narrowed arteries, responsible for angina and other symptoms of the disease, by angioplasty or surgery.
Introduction of metal scaffolds called 'stents' in the past few decades revolutionised the angioplasty technique, and has made it the most popular treatment today for CAD.
However these stents are prone to becomin narrow and obstructed after implanataion, causing symptoms and non-fatal heart attacks in some patients.
Introduction of stents that slowly release drugs locally to minimize this process, called 'drug-eluting stents'(DES)he past few years has been one of the biggest breakthroughs in the field of cardiology.
However ven the current available DES are still prone to narrowing in high-risk patients, like those with diabetes, and also have a higher chance for sudden blockage by a blood clot even many years later after insertion.
Thus it is important to develop technology for more efficacious and safer DES.This includes safer drugs, better stent design and delivery, and more inert platforms for drug release We hypothesise that a new stent made with nanoporous particle with better polymer for drug release will prove to be safer and more efficacious alternative to currently available DES.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment
200
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Balram Bhargava, MD, DM
- Phone Number: 91-11-26588663
- Email: balrambhargava@yahoo.com
Study Locations
-
-
Delhi
-
New Delhi, Delhi, India, 110029
- Recruiting
- All India Institute of Medical Sciences
-
Principal Investigator:
- Balram Bhargava, MD, DM
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or non-pregnant female 2: 18 years of age (note: females of child bearing potential must have a negative pregnancy test within 7 days of treatment and must use effective pregnancy avoidance until the 6 month angiogram is completed)
- Have chest pain consistent with angina pectoris or a history of documented myocardial infarction or documented silent ischemia
- Treatment of a native vessel de novo coronary lesion (only 1 single study lesion/patient)
- Target vesseI2.5mm-4.0mm in diameter (visual estimate)
- Target lesion length::: 12mm (visual estimate)
- Target lesion stenosis> 50% and < 100% (visual estimate)
- At least TIMI grade II coronary flow
- Acceptable candidate for CABG surgery
- Patient is willing to come back for a follow-up evaluations including repeat cardiac catheterization 5-7 months after treatment
- Patient must provide written informed consent prior to the index procedure using a form that is approved by the local Ethics Committee
Exclusion Criteria:
- Patient has experienced an acute myocardial infarction (Q wave or non-Q wave) within 72 hours prior to the index procedure with CK enzymes 2: 2x the local laboratory upper limit of normal, with the presence of CK- MB levels elevated above the local laboratory upper limit of normal;
- Unprotected left main coronary disease with> 50% stenosis;
- Significant (> 50%) stenosis proximal or distal to the target lesion that might require revascularization or impede runoff;
- Ostial location of the target lesion;
- Angiographic evidence of thrombus within the target lesion;
- Severely calcified'lesion which cannot be successfully predilated;
- Documented L VEF < 25%, or clinically significant congestive cardiac failure;
- Totally occluded vessel;
- Impaired renal function (creatinine> 0.27mmol/L) at the time of treatment;
- Pretreatment with devices other than balloon angioplasty;
- Excessive tortuosity proximal to the lesion which makes stent delivery and deployment uncertain;
- Target lesion involves a bifurcation including a diseased side branch> 2.5mm in diameter that would require treatment;
- Prior stenting within 5mm of the target lesion;
- Patient is a recipient of a heart transplant;
- Patient has a life expectancy < 12 months;
- Known allergies to clopidogrel bisulfate (Plavix@), ticlopidine (Ticlid@), Cobalt Chromium alloy and Paclitaxol that cannot be medically managed;
- In the investigator's opinion, any significant medical condition which may interfere with the patient's optimal participation in this study;
- Currently participating in an investigational drug or device study that has not completed the primary endpoint;
- Intervention of another coronary lesion has occurred within 30 days before or is planned within 30 days after the index procedure.
- In the investigator's opinion, the lesion is not suitable for stenting
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
In-stent late loss as compared historically to other DES, within the stented segment post-procedure and at 6-9-month follow-up
|
Secondary Outcome Measures
Outcome Measure |
---|
Major adverse cardiac events
|
Stent thrombosis rate (acute, subacute, or chornic)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Balram Bhargava, MD, DM, All India Institute of Medical Sciences, New Delhi
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R; RAVEL Study Group. Randomized Study with the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients with de Novo Native Coronary Artery Lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002 Jun 6;346(23):1773-80. doi: 10.1056/NEJMoa012843.
- Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME; TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004 Jan 15;350(3):221-31. doi: 10.1056/NEJMoa032441.
- Bhargava B, Reddy NK, Karthikeyan G, Raju R, Mishra S, Singh S, Waksman R, Virmani R, Somaraju B. A novel paclitaxel-eluting porous carbon-carbon nanoparticle coated, nonpolymeric cobalt-chromium stent: evaluation in a porcine model. Catheter Cardiovasc Interv. 2006 May;67(5):698-702. doi: 10.1002/ccd.20698.
- van der Giessen WJ, Lincoff AM, Schwartz RS, van Beusekom HM, Serruys PW, Holmes DR Jr, Ellis SG, Topol EJ. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation. 1996 Oct 1;94(7):1690-7. doi: 10.1161/01.cir.94.7.1690.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2007
Study Completion
October 1, 2007
Study Registration Dates
First Submitted
January 29, 2007
First Submitted That Met QC Criteria
January 29, 2007
First Posted (Estimate)
January 30, 2007
Study Record Updates
Last Update Posted (Estimate)
January 30, 2007
Last Update Submitted That Met QC Criteria
January 29, 2007
Last Verified
January 1, 2007
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Stenosis
-
Biotronik (Beijing) Medical Device Ltd.Biotronik AGEnrolling by invitationNative Coronary Artery Stenosis | In-Stent Stenosis (Restenosis) of Coronary Artery StentChina
-
Axetis AGUnknownNative Coronary Artery StenosisNetherlands
-
Fundación Pública Andaluza Progreso y SaludUnknownUnprotected Left Main Coronary Artery StenosisSpain
-
ECRI bvBoston Scientific Corporation; Philips HealthcareActive, not recruitingLeft Main Coronary Artery StenosisSpain, United Kingdom, Italy
-
Institut Mutualiste MontsourisCompletedLeft Main Coronary Artery StenosisFrance
-
Tryton Medical, Inc.UnknownLeft Main Coronary Artery StenosisGermany
-
Columbia UniversityRecruitingLeft Anterior Descending Coronary Artery StenosisUnited States
-
San Luigi Gonzaga HospitalRecruitingCoronary Disease | STEMI | Coronary Artery Ectasia | Right Coronary Artery Occlusion | Right Coronary Artery StenosisSpain, Italy
-
Das Radiologische ZentrumHeidelberg UniversityRecruiting
-
Concept Medical Inc.Cardiovascular Research Foundation, New YorkNot yet recruitingCardiovascular Diseases | Coronary Artery Disease | Native Coronary Artery Stenosis
Clinical Trials on drug eluting nonpolymeric nanoporous stent
-
Seoul National University Bundang HospitalKorea University Anam Hospital; Korea University Guro Hospital; Gachon University... and other collaboratorsCompletedMyocardial Ischemia | Coronary Artery DiseaseKorea, Republic of
-
Henan Institute of Cardiovascular EpidemiologyRecruiting
-
Fatebenefratelli and Ophthalmic HospitalCompletedCardiovascular Diseases
-
Aarhus University Hospital SkejbyMedtronic Cardiovascular; Biosensors InternationalCompletedCoronary Artery Disease | Angina PectorisDenmark
-
Hospital Universitari Vall d'Hebron Research InstituteB.Braun Surgical SACompleted
-
Medtronic VascularMedtronic Japan Co., Ltd.CompletedMyocardial Ischemia | Cardiovascular Diseases | Coronary Artery Disease | Arterial Occlusive DiseasesJapan
-
Boston Scientific CorporationLabcoat, Ltd.CompletedCoronary Artery DiseaseItaly
-
University of SaskatchewanUnknown
-
Bon-Kwon KooSeoul St. Mary's Hospital; Chonnam National University Hospital; Seoul National... and other collaboratorsRecruitingCoronary Artery Disease | Multi Vessel Coronary Artery DiseaseKorea, Republic of
-
Second Affiliated Hospital, School of Medicine,...Unknown